Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Evelo Biosciences Inc (EVLO) COM USD0.001

Sell:$6.01 Buy:$6.06 Change: $0.64 (11.92%)
NASDAQ:0.20%
Market closed |  Prices as at close on 23 January 2020 | Switch to live prices |
Sell:$6.01
Buy:$6.06
Change: $0.64 (11.92%)
Market closed |  Prices as at close on 23 January 2020 | Switch to live prices |
Sell:$6.01
Buy:$6.06
Change: $0.64 (11.92%)
Market closed |  Prices as at close on 23 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Contact details

Address:
620 Memorial Dr Ste 200
CAMBRIDGE
02139-4815
United States
Telephone:
+1 (617) 8708281
Website:
https://evelobio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EVLO
ISIN:
US2997341035
Market cap:
$148.24 million
Shares in issue:
32.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Epstein
    Chairman of the Board
  • Simba Gill
    Chief Executive Officer, Director
  • Jonathan Poole
    Chief Financial Officer
  • Mark Bodmer
    Chief Scientific Officer, President of Research and Development
  • Duncan McHale
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.